- Starpharma rises on a partnership with Merck on DEP-Antibody Drug Conjugates.
- AstraZeneca AZD0466 (with Starpharma DEP technology) Phase 1 trial goes global.
- Viraleze, registered in Europe and positioned as a COVID preventative/early treatment, stable at room temperature and compatible with handbag/briefcase; launch in Europe March.
- Lots of news flow for Starpharma means rising share price, but the share price is volatile, with pullbacks on no news. Timing entry is worth considering.
For further details see:
Starpharma Up With News, Down With None; Timing Entry Makes Sense